Stock of the Day

Today's Trend

Tilray Brands, Inc. (NASDAQ: TLRY) remains under pressure, with the latest decline primarily attributed to an analyst downgrade. Investors are also weighing positive progress in Tilray’s medical-cannabis operations against ongoing losses, negative free cash flow and weaker cannabis revenue.

• Tilray Medical received approval from Portugal’s INFARMED regulator to conduct microbiological and chemical/physical quality testing at its Cantanhede facility. Bringing EU-GMP testing in-house could reduce reliance on external laboratories, streamline production and accelerate product launches across regulated international markets. Tilray Medical Gains Approval for In-House Quality Testing at Portugal Facility
• The company’s BrewDog beer operations contributed to higher first-quarter revenue, while Tilray expects its beer assets and international cannabis business to support future growth. BrewDog Acquisition Boosts Tilray's Stock Q1 Performance
• The Portugal approval strengthens Tilray’s medical-cannabis supply chain and quality-control capabilities, but the near-term financial impact and resulting revenue contribution were not quantified. Tilray Medical Portugal Quality Testing Approval
• Tilray Brands’ stock declined after an analyst downgrade, signaling weaker expectations or valuation concerns and adding selling pressure. The report did not provide further details on the analyst’s target price or rationale. Tilray Brands Stock Price Down Following Analyst Downgrade
• Despite BrewDog-related revenue growth, Tilray reported declining cannabis revenue, a net loss and negative free cash flow. Those results reinforce concerns about profitability and execution, particularly as the stock trades near its 12-month low and below its 50-day and 200-day moving averages. BrewDog Acquisition Boosts Tilray's Stock Q1 Performance